SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Incyte Genomics Inc
INCY
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Last trade$119.90
Day change-$0.37 (-0.31%)
Day range$118.00 – $121.40
Volume808,502
Market cap$24.51B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$24.51B
Price / earnings
60.77×
Price / book
4.34×
Price / sales
4.08×
EV / sales
3.54×
EV / EBITDA
26.51×
Profitability
Earnings per share
$1.98
Return on assets
5.54%
Return on equity
7.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
3.84×
Quick ratio
3.75×
Cash ratio
2.28×
Cash flow
Price / cash flow
32.91×
Price / free cash flow
35.79×
Free cash flow
$684.87M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INCY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.56B
$1.67B
$1.27B
$1.51B
$1.37B
$1.22B
$1.05B
$1.18B
Cost of revenue
$108.74M
$104.96M
$104.52M
$121.18M
$99M
$78.77M
$73.19M
$88.49M
Gross profit
$1.45B
$1.57B
$1.17B
$1.39B
$1.27B
$1.14B
$979.71M
$1.09B
Selling, general and administrative
$364.27M
$351.74M
$328.09M
$390.41M
$329.08M
$331.02M
$325.69M
$326.71M
Research and development
$1.79B
$516.95M
$515.9M
$611.37M
$506.58M
$494.92M
$437.28M
$466.03M
Total operating expenses
$2.16B
$871.18M
$867.04M
$1.05B
$823.46M
$606.45M
$774.54M
$788.7M
Operating income
-$708.36M
$697.9M
$301.12M
$335.86M
$443.52M
$530.31M
$205.17M
$301.51M
Interest expense
-$605K
-$582K
-$569K
-$582K
-$592K
-$594K
-$660K
-$419K
Income before taxes
-$688.85M
$751.51M
$343.6M
$389.94M
$482.31M
$558.01M
$234.19M
$313.72M
Income taxes
$95.96M
$165.91M
$40.27M
$90.66M
$58.14M
$153.01M
$75.99M
$112.51M
Net income
-$784.8M
$585.61M
$303.33M
$299.28M
$424.17M
$405M
$158.2M
$201.21M
Net income attributable to common shareholders
-$784.8M
$585.61M
$303.33M
$299.28M
$424.17M
$405M
$158.2M
$201.21M
EBITDA
-$684.19M
$724.37M
$348.13M
$413.99M
$467.54M
$310.98M
$227.53M
$300.4M
Basic earnings per share
-$3.86
$2.92
$1.52
$1.52
$2.17
$2.09
$0.82
$1.04
Diluted earnings per share
-$3.86
$2.81
$1.47
$1.46
$2.11
$2.04
$0.80
$1.00
Recent news
Company coverage with links to the original publishers.
Incyte announced European Commission approval for Povofortay (povorcitinib) 45 mg and 75 mg for treating moderate to severe hidradenitis suppurativa in adults. The approval is based on STOP-HS1 and STOP-HS2 studies showing durable efficacy through Week 54, with up to 71.4% of patients achieving HiSCR50. Povofortay is the first once-daily oral treatment approved in the EU for this indication. FDA review for U.S. approval is ongoing, with anticipated approval in Q1 2027.
Incyte Corporation and Genmab A/S have entered into a clinical trial collaboration to evaluate a combination therapy for first-line treatment of metastatic colorectal cancer (mCRC) with KRAS G12D mutations. The combination includes Incyte's INCB161734 (KRAS G12D inhibitor), Genmab's petosemtamab (bispecific antibody), and standard chemotherapy. Genmab will lead the phase I/II study while Incyte provides the drug and shares development costs.
A comparison of two medical-biomedical and genetics stocks reveals that Incyte (INCY) is the more attractive value investment option. INCY holds a Zacks Rank #2 (Buy) with improving earnings outlook and a Value grade of B, while Techne (TECH) has a Zacks Rank #3 (Hold) and Value grade of D. INCY's lower PEG ratio (2.67 vs 7.53) and P/B ratio (3.94 vs 5.38) suggest better valuation metrics.
Incyte Corporation agreed to acquire Vega Therapeutics for $1.25 billion upfront to add VGA039, a late-stage monoclonal antibody candidate for von Willebrand disease, to its hematology portfolio. The deal could reach $2 billion with milestone payments. VGA039, in Phase 3 development, has potential to become the first subcutaneous prophylactic treatment for VWD and analysts project blockbuster commercial potential with over $1 billion market opportunity.